Brands of Fosfomycin
Fosmol, Pharma Bavaria International
Fosfomycin is indicated for the treatment of the following infections in adults and children including neonates :
– Complicated urinary tract infections
– Nosocomial lower respiratory tract infections
– Bacterial meningitis
– Bacteraemia that occurs in association with, or is suspected to be associated with, any of the infections listed above.
Fosfomycin should be used only when it is considered inappropriate to use antibacterial agents that are commonly recommended for the initial treatment of the infections listed above, or when these alternative antibacterial agents have failed to demonstrate efficacy.
Consideration should be given to official guidance on the appropriate use of antibacterial agents.
Fosfomycin is contraindicated in patients with known hypersensitivity to the drug.
No drug-drug interaction studies have been performed with fosfomycin. To date, no clinically relevant pharmacological interactions between fosfomycin and other agents (drugs, stimulants or foodstuffs) have been reported.
Combination with other antibiotics
In-vitro tests have shown that the combination of fosfomycin with a β-lactam antibiotic such as penicillin, ampicillin, cefazolin or the class of carbapenems, usually shows an additive to synergistic effect. The same applies to the combination of fosfomycin with most anti-staphylococcal (linezolid, quinupristin/dalfopristin, moxifloxacin) agents in the treatment of staphylococcal infections. The combination of fosfomycin with aminoglycosides has predominantly indifferent to additive effects.
ADVERSE DRUG REACTIONS:
angioedema, aplastic anemia, asthma (exacerbation), cholestatic jaundice, hepatic necrosis, and toxic megacolon.
anaphylaxis and hearing loss.
Reporting of suspected adverse reactions:
The PPB Department of Pharmacovigilance was set up with a vision to develop, implement and continuously upgrade an appropriate system for detecting, reporting, and monitoring adverse drug reactions (ADRs) and other relevant problems with medicines in Kenya. The department strives to ensure the safety and efficacy of pharmaceutical products in Kenya.
Reporting suspected adverse reactions after authorization of the medicinal product are important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals/ Patients are encouraged to report any suspected adverse reactions via Pharmacovigilance Yellow Form, firstname.lastname@example.org or clicking below button:
Fosfomycin in Kenya
Fosfomycin in Kenya
brand names of Fosfomycin in Kenya
Where to buy Fosfomycin in Kenya
Price of Fosfomycin in Kenya
Clinical | Pharmacokinetic data
Pregnancy Category: B (No risk in non-human studies)
Routes of Administration: Oral
Bioavailability: 30–37% (by mouth, fosfomycin tromethamine); varies with food intake
Protein Binding: Nil
Onset of Action: Not Available
Elimination Half life: 5.7 hours (mean)
Excretion: Kidney and fecal, unchanged
Legal Status | Dosage forms & Strengths
Prescription only Medicine (POM) , ℞-only
Narcotic Drugs and Psychotropic Substances (Control ) Act Schedule:
This drug is not a controlled substance under Narcotic Drugs and Psychotropic Substances (Control ) Act
Dosage Forms | Strengths:
3000mg granules for Oral solution
|CompTox Dashboard (EPA)|
- PPB Drugs Retention Register
- Patel, Sanjay S., Julia A. Balfour, and Harriet M. Bryson. “Fosfomycin tromethamine.” Drugs 53.4 (1997): 637-656.
- Kahan, Frederick M., et al. “The mechanism of action of fosfomycin (phosphonomycin).” Annals of the New York Academy of Sciences 235.1 (1974): 364-386.
- Falagas, Matthew E., et al. “Fosfomycin: use beyond urinary tract and gastrointestinal infections.” Clinical infectious diseases 46.7 (2008): 1069-1077.
- Dijkmans, Anneke Corinne, et al. “Fosfomycin: pharmacological, clinical and future perspectives.” Antibiotics 6.4 (2017): 24.